Want to see IN:RPGLIFE full AI Analyst Report?
RPGLIFE Stock Chart & Stats
₹2913.00
-₹8.90(-0.30%)
At close: 4:00 PM EDT
₹2913.00
-₹8.90(-0.30%)
Day’s Range― - ―
52-Week Range₹1,731.25 - ₹3,080.90
Previous CloseN/A
Volume16.15K
Average Volume (3M)3.23K
Market Cap
₹42.96B
Enterprise Value₹28.04K
Total Cash (Recent Filing)₹2.74B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)35.5
Beta0.74
Next Earnings
Oct 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.93%
Share Statistics
EPS (TTM)72.34
Shares Outstanding16,539,015
10 Day Avg. Volume8,652
30 Day Avg. Volume3,228
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)5.08
Price to Sales (P/S)4.34
P/FCF Ratio-38.40K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageConservative leverage limits financing risk and preserves flexibility to fund product development, manufacturing capacity and working capital. This gives the branded-formulations business resilience if industry conditions or operating performance weaken.
Resilient Revenue GrowthA multi-year revenue growth record indicates sustained demand for the company’s formulations and provides a durable base for operations. Continued prescription uptake and distribution reach can support growth beyond temporary market movements.
Strong Return On EquitySustained, healthy returns on equity suggest the company has historically converted its capital base into profits effectively. Combined with low leverage, this indicates operating strength rather than returns driven primarily by financial risk.
Bears Say
Weakening Cash ConversionDeteriorating cash conversion can constrain internally funded growth and may indicate higher working-capital requirements or capital spending. If persistent, it could reduce financial flexibility despite continued accounting profitability.
Recent Margin CompressionMargin compression directly reduces the earnings generated from each unit of revenue and makes results more sensitive to costs, pricing and product mix. Continued variability would weaken the durability of the company’s earnings power.
Declining Earnings Per ShareA substantial decline in EPS signals that recent business growth has not translated into comparable per-share earnings. Unless profitability stabilizes, weaker earnings can limit reinvestment capacity and reduce the company’s ability to compound shareholder value.
RPG Life Sciences Limited News
RPGLIFE FAQ
What was RPG Life Sciences Limited’s price range in the past 12 months?
RPG Life Sciences Limited lowest stock price was ₹1731.25 and its highest was ₹3080.90 in the past 12 months.
What is RPG Life Sciences Limited’s market cap?
RPG Life Sciences Limited’s market cap is ₹42.96B.
When is RPG Life Sciences Limited’s upcoming earnings report date?
RPG Life Sciences Limited’s upcoming earnings report date is Oct 21, 2026 which is in 54 days.
How were RPG Life Sciences Limited’s earnings last quarter?
RPG Life Sciences Limited released its earnings results on Jul 28, 2026. The company reported ₹18.598 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is RPG Life Sciences Limited overvalued?
According to Wall Street analysts RPG Life Sciences Limited’s price is currently Overvalued.
Does RPG Life Sciences Limited pay dividends?
RPG Life Sciences Limited pays a Notavailable dividend of ₹24 which represents an annual dividend yield of 0.93%. See more information on RPG Life Sciences Limited dividends here
What is RPG Life Sciences Limited’s EPS estimate?
RPG Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RPG Life Sciences Limited have?
RPG Life Sciences Limited has 16,539,015 shares outstanding.
What happened to RPG Life Sciences Limited’s price movement after its last earnings report?
RPG Life Sciences Limited reported an EPS of ₹18.598 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.283%.
Which hedge fund is a major shareholder of RPG Life Sciences Limited?
Currently, no hedge funds are holding shares in IN:RPGLIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RPG Life Sciences Limited
RPG Life Sciences Limited operates as a fully integrated pharmaceutical enterprise, engaged in the development, production, and commercialization of branded drug formulations, generic medications, and synthetic active pharmaceutical ingredients (APIs) for both the Indian and global markets. The company provides synthetic APIs for diverse medical applications, including immunosuppression, psychiatric conditions, cardiac health (anti-anginals), parasitic infections (anthelmentics), seizure management (anticonvulsants), and muscle spasm relief (antispasmodics). While its generics portfolio primarily centers on immunosuppressant treatments, its finished dosage formulations address a wide spectrum of therapeutic areas, such as nephrology, rheumatology, oncology, gastroenterology, cardiovascular health, diabetology, orthopedics, neuropsychiatry, and respiratory conditions, among many others. Established in 1968 with its headquarters in Mumbai, India, the company adopted its current name in February 2008, having previously been known as RPG Pharmaceuticals Limited. RPG Life Sciences Limited functions as a subsidiary of Nucleus Life Trust.
Technical Analysis
Bliss Gvs Pharma Limited
―
Hikal Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Solara Active Pharma Sciences Ltd.
―
Unichem Laboratories Limited
―